Login to Your Account

Other News To Note

Friday, December 7, 2012
• Arno Therapeutics Inc., of Flemington, N.J., has identified a new immunohistochemistry technique for identifying activated progesterone receptors in breast cancer tumors that may be predictive of response to treatment with onapristone, an investigational progestin receptor antagonist being developed by Arno that has demonstrated antitumor activity in preclinical and clinical studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription